We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024
25 Apr 2024 - 27 Apr 2024

New AI Blood Test Could Become Game Changer for Bowel Cancer Diagnosis

By LabMedica International staff writers
Posted on 10 Mar 2023
Print article
Image: A fast, inexpensive and scalable test for the early diagnosis of bowel cancer is currently under development (Photo courtesy of Pexels)
Image: A fast, inexpensive and scalable test for the early diagnosis of bowel cancer is currently under development (Photo courtesy of Pexels)

Colorectal cancer (CRC), also referred to as bowel cancer, is the world's third most common cancer and the fourth leading cause of death. It is responsible for approximately 1.4 million new cases and 700,000 deaths every year. In Europe, bowel cancer is the second most prevalent cancer, with 450,000 cases annually. Developed countries have seen an increase in incidence of CRC, and the figures remain high. Early detection of CRC has always been crucial in saving lives. Now, the introduction of a fast, affordable, and scalable test for the early detection of bowel cancer could revolutionize the approach to the diagnosis and screening of this disease.

CanSense Ltd. (Swansea, UK) is harnessing artificial intelligence-based modeling (AI) to create a rapid, affordable, and versatile test that can detect bowel cancer in its early stages, save lives and reduce distress. The test could help dramatically reduce the mortality rate of CRC via early stage diagnosis. It also has the potential to reduce the need for unnecessary invasive colonoscopies and the associated financial burden on healthcare providers.

Negative colonoscopy procedures are associated with considerable economic costs, estimated to be a minimum of USD 4.2 billion worldwide. The blood test can serve as a tool to aid healthcare professionals in determining the necessity of further colonoscopy examinations. From the viewpoint of an anxious symptomatic patient, this approach to CRC triage offers significant advantages. The test can yield quick and accurate results, identifying patients requiring immediate and priority treatment. For those given a negative diagnosis, it effectively eliminates the need for colonoscopy procedures and quickly reduces their anxiety.

Related Links:
CanSense Ltd. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.